Heidelberg Pharma AG is allowed to initiate a Phase I/IIa clinical study in the US to evaluate the dosing, safety and anti-tumour efficacy of its lead candidate HDP-101 in multiple myeloma.
16 partners from academia and industry will closely collaborate to prepare a future generation of scientists with outstanding skills in both machine learning and chemistry, to create new AI methods for drug research.
Ascenion, technology transfer partner of Hannover Medical School (MHH), has supported the conclusion of a collaboration and licence agreement between MHH and Novo Nordisk.
As part of its ‘GO-Bio initial’ programme, the BMBF has awarded Ascenion funding for its 'Life Science Digital Hub' concept to improve support for GO-Bio initial applicants.
Ascenion’s portfolio company HepaRegeniX achieves an important preclinical milestone indicating beneficial therapeutic effects of its lead candidate in certain liver carcinomas.
An innovative approach to combat infections caused by Staphylococcus aureus will receive funding of initially 1.33 million USD plus an additional 7.44 million USD, depending on project progress. It is jointly developed by the HZI and the LDC.
Ascenion welcomes a new colleague to the Munich office: Stefanie Danzer joined in October 2020 to support the back office in event management and corporate communications.
Ascenion will support eight members and four partners of the Innovative Training Network (ITN) ‘SMABEYOND’ in all aspects relating to the intellectual property and potential commercialization of their work.
Ascenion’s portfolio company iThera gained regulatory approval for a pivotal trial evaluating its MSOT imaging technology for the assessment of colon inflammation. If successful, it could provide a superior, non-invasive alternative to colonoscopy.
How is the German start-up sector doing? Are there ‘zombies’ here too – as in the USA? And what should we be looking out for? A number of heads of German technology transfer organisations were interviewed for this overview, including Ascenion’s Christian Stein.